This review postulates why their modulation by GLP1-Ras may mediate the beneficial metabolic effects of these drugs, which have increased attention to their emerging role as pharmacotherapy for MASLD. Here, GLP1R is linked to metabolic dysfunction-associated steatotic liver disease.